Literature DB >> 22063790

Impact of Helicobacter pylori infection on severity of psoriasis and response to treatment.

Nahide Onsun1, Hande Arda Ulusal, Ozlem Su, Ismet Beycan, Dilek Biyik Ozkaya, Mustafa Senocak.   

Abstract

The aims of this study were to determine the prevalence of H. pylori seropositivity in patients with psoriasis, to evaluate the relationship between PASI (Psoriasis Area and Severity Index) scores and H. pylori infection, and to assess the impact of H. pylori infection on the response to treatment. A total of 300 patients with psoriasis and 150 non-psoriatic healthy controls were enrolled in the study. Patient PASI scores were recorded and H. pylori stool antigen tests performed in both patients and controls. Fifty patients with H. pylori infections were randomly assigned to one of two groups, one of which received acitretin with H. pylori treatment and the other acitretin alone. Statistical analyses were performed using chi-square and logistic regression tests. PASI scores were significantly higher in patients with H. pylori infections. Treatment aimed at eradicating H. pylori infection enhanced the effectiveness of acitretin therapy and shortened response times. Our results suggest that H. pylori infection plays a role in the severity of psoriasis, and that eradicating such infections enhances the effectiveness of psoriasis treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22063790     DOI: 10.1684/ejd.2011.1579

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  16 in total

Review 1.  Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment.

Authors:  Traci L Testerman; James Morris
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 2.  Helicobacter pylori and skin autoimmune diseases.

Authors:  Eli Magen; Jorge-Shmuel Delgado
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 3.  Helicobacter pylori and autoimmune disease: cause or bystander.

Authors:  Daniel S Smyk; Andreas L Koutsoumpas; Maria G Mytilinaiou; Eirini I Rigopoulou; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

4.  Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis.

Authors:  Davide Giuseppe Ribaldone; Giorgio Saracco; Rinaldo Pellicano
Journal:  An Bras Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.896

5.  Relationship of Helicobacter pylori seroprevalence with the occurrence and severity of psoriasis.

Authors:  Priscila Miranda Diogo Mesquita; Augusto Diogo; Miguel Tanus Jorge; Alceu Luiz Camargo Villela Berbert; Sônia Antunes de Oliveira Mantese; José Joaquim Rodrigues
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

Review 6.  Helicobacter pylori and extragastric diseases: A review.

Authors:  Antonietta Gerarda Gravina; Rocco Maurizio Zagari; Cristiana De Musis; Lorenzo Romano; Carmelina Loguercio; Marco Romano
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

Review 7.  Therapy of Helicobacter pylori: present medley and future prospective.

Authors:  Amin Talebi Bezmin Abadi
Journal:  Biomed Res Int       Date:  2014-04-01       Impact factor: 3.411

Review 8.  Current knowledge on psoriasis and autoimmune diseases.

Authors:  Nilmarie Ayala-Fontánez; David C Soler; Thomas S McCormick
Journal:  Psoriasis (Auckl)       Date:  2016-02-22

Review 9.  Association between Psoriasis and Helicobacter pylori Infection: A Systematic Review and Meta-analysis.

Authors:  Wai Chung Yong; Sikarin Upala; Anawin Sanguankeo
Journal:  Indian J Dermatol       Date:  2018 May-Jun       Impact factor: 1.494

10.  Relationship between Helicobacter pylori infection and psoriasis: a nationwide population-based longitudinal cohort study.

Authors:  Meng-Che Wu; Kevin Sheng-Kai Ma; Huang-Hsi Chen; Jing-Yang Huang; James Cheng-Chung Wei
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.